Fusion Antibodies plc (AIM:FAB)
London
· Delayed Price · Currency is GBP · Price in GBX 14.00
0.00 (0.00%)
At close: Feb 27, 2026
Fusion Antibodies Revenue
Fusion Antibodies had revenue of 838.00K GBP in the half year ending September 30, 2025, with 54.90% growth. This brings the company's revenue in the last twelve months to 1.60M, down -11.43% year-over-year. In the fiscal year ending March 31, 2025, Fusion Antibodies had annual revenue of 1.97M with 72.98% growth.
Revenue (ttm)
1.60M
Revenue Growth
-11.43%
P/S Ratio
10.97
Revenue / Employee
66.50K
Employees
24
Market Cap
17.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.97M | 829.00K | 72.98% |
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SkinBioTherapeutics | 4.64M |
| Aptamer Group | 1.20M |
| Oxford BioDynamics | 1.10M |
| Arecor Therapeutics | 5.06M |
| CRISM Therapeutics | 25.00K |
| ImmuPharma | -69.96K |
| IXICO | 6.53M |
| Futura Medical | 7.93M |